Zuranolone (SAGE-217; SAGE Therapeutics) has been granted priority review for treatment against postpartum depression and major depressive …
FDA accepts NDA for zuranolone against depression – Contemporary OB/GYN
Share This Story, Choose Your Platform!
About the Author:
